Phil Taylor, Author at - Page 4 of 272

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from

Lilly partners with Sidekick in digital health alliance

https://pharmaphorum.com/news/lilly-partners-with-sidekick-in-digital-health-alliance/

MorphoSys slims down, narrowing its focus to cancer

Phil Taylor HIBio, Immunology and inflammation, licensing, MorphoSys, nephrology, Oncology, partnering 0 Comment

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in

MorphoSys slims down, narrowing its focus to cancer

https://pharmaphorum.com/news/morphosys-slims-down-narrowing-its-focus-to-cancer/

Market Access/ News/ News

Hansa gets NICE okay for Idefirix in kidney transplant patients

Phil Taylor Hansa Biopharma, Idefirix, nephrology, NHS, NICE, transplant 0 Comment

Sweden’s Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared

Hansa gets NICE okay for Idefirix in kidney transplant patients

https://pharmaphorum.com/news/hansa-gets-nice-okay-for-idefirix-in-kidney-transplant-patients/

Digital/ News/ News

HiDoc raises $7m and names new CEO as digital tool for IBS launches

Phil Taylor Cara Care, digital, digital health, digital therapeutics, financing, HiDoc Technologies, irritable bowel syndrome, senior management 0 Comment

HiDoc Technologies has secured a cash injection of $7 million to help with the launch of its Cara

HiDoc raises $7m and names new CEO as digital tool for IBS launches

https://pharmaphorum.com/news/hidoc-raises-7m-and-names-new-ceo-as-digital-tool-for-ibs-launches/

News/ News/ R&D

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

Phil Taylor AC Immune, Alzheimer's disease, amyloid, crenezumab, gantenerumab, Genentech, Roche 0 Comment

The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

https://pharmaphorum.com/news/another-amyloid-miss-in-alzheimers-as-roches-crenezumab-fails-trial/

Market Access/ News/ News/ News/ Patients

FDA advisors back COVID jabs for very young children

Phil Taylor access, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, paediatric, Pfizer, regulatory 0 Comment

The FDA’s vaccines advisors have voted in favour of extending the use of mRNA-based COVID-19 vaccine from Moderna

FDA advisors back COVID jabs for very young children

https://pharmaphorum.com/news/fda-advisors-back-covid-jabs-for-very-young-children/

News/ News/ News/ Oncology/ R&D

Boehringer takes option on masked cytokine specialist Trutino

Phil Taylor Boehringer Ingelheim, cytokine therapies, immuno-oncology, M&A, Oncology, Trutino Biosciences 0 Comment

Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop

Boehringer takes option on masked cytokine specialist Trutino

https://pharmaphorum.com/news/boehringer-takes-option-on-masked-cytokine-specialist-trutino/

News/ News/ Sales and Marketing

Mallinckrodt tries again with kidney drug terlipressin

Phil Taylor kidney disease, Mallinckrodt, regulatory, terlipressin 0 Comment

Manufacturing problems wreaked havoc with Mallinckrodt’s first attempt to secure FDA approval of its treatment candidate terlipressin for

Mallinckrodt tries again with kidney drug terlipressin

https://pharmaphorum.com/news/mallinckrodt-tries-again-with-kidney-drug-terlipressin/

Market Access/ News/ News

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

Phil Taylor anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE 0 Comment

Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

https://pharmaphorum.com/news/nice-backs-astellas-oral-therapy-evrenzo-for-anaemia-in-kidney-disease/

Trending

About Phil Taylor

Posts by Phil Taylor:

Lilly partners with Sidekick in digital health alliance

MorphoSys slims down, narrowing its focus to cancer

Hansa gets NICE okay for Idefirix in kidney transplant patients

HiDoc raises $7m and names new CEO as digital tool for IBS launches

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

FDA advisors back COVID jabs for very young children

Boehringer takes option on masked cytokine specialist Trutino

Mallinckrodt tries again with kidney drug terlipressin

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

Trending

About Phil Taylor

Posts by Phil Taylor:

Login